GeneSystem Co

GeneSystem Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is 0.25. In the previous year, Long-Term Debt to Equity Ratio was 0.12 — a change of 110.32% (higher).

LT Debt/Equity

0.25

YoY

110.32%

Last updated:

Long-Term Debt to Equity Ratio of GeneSystem Co is 2025 0.25 . Long-Term Debt to Equity Ratio of GeneSystem Co was 2024 0.12 . It decreases by 110.32% higher compared to the previous year.

The GeneSystem Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
-0.36 KRW
Jan 1, 2019
-0.15 KRW
Jan 1, 2020
0.24 KRW
Jan 1, 2021
0.07 KRW
Jan 1, 2022
0.09 KRW
Jan 1, 2023
0.11 KRW
Jan 1, 2024
0.12 KRW
Jan 1, 2025
0.25 KRW
The GeneSystem Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.25+110.32%
0.12+4.04%
0.11+28.72%
0.09+24.26%
0.07-71.07%
0.24-259.65%
-0.15-56.99%
-0.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Long-Term Debt to Equity Ratio of GeneSystem Co is 0.25 in 2025.

Long-Term Debt to Equity Ratio of GeneSystem Co changed from 0.12 to 0.25, representing a 110.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GeneSystem Co

All Key Metrics — GeneSystem Co